Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	17.09B
Revenue (ttm)	4.52B
Net Income (ttm)	254.63M
Shares Out	521.85M
EPS (ttm)	0.45
PE Ratio	73.29
Forward PE	26.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	228,982
Average Volume	598,655
Open	32.74
Previous Close	32.74
Day's Range	32.48 - 32.92
52-Week Range	30.54 - 47.30
Beta	1.56
RSI	42.11
Earnings Date	Oct 22, 2025

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR